CHICAGO, Oct. 29 /PRNewswire/ -- Rosalind Franklin University of Medicine and Science and the plaintiffs who challenged the University over the discontinuation of a breast cancer vaccine study have agreed to settle their lawsuit, with Federal Magistrate Judge Martin Ashman’s assistance. The settlement is subject to approval by the University’s Board of Trustees.
Under the proposed agreement, the University has agreed to fund the plaintiffs’ pursuit of FDA approval of the vaccine that was the subject of the lawsuit. Robert P. Vogt, an attorney for the University, explained, “The University believes that the prior decision of its Institutional Review Board regarding the T/tn vaccine study was correct. The Plaintiffs, however, contend that another Institutional Review Board will support the T/tn vaccine study. The University is pleased that this settlement gives the plaintiffs a fresh opportunity to pursue the T/tn vaccine study and also gives them the resources to do it.”
Plaintiffs’ lead counsel Robert Cummins said that his clients agreed to settle because, with FDA approval, they will now be able to obtain the vaccine they believe was protecting them from the recurrence of breast cancer. Cummins stated, “Our focus was on getting these women the vaccine they needed. Under our settlement agreement, we are giving them the chance to do that.”
Rosalind Franklin University of Medicine and Science
CONTACT: Kelly Klopp for Rosalind Franklin University of Medicine andScience, +1-312-952-1108
